Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
MedImmune LLC
SWOG Cancer Research Network
The Royal Wolverhampton Hospitals NHS Trust
University of California, San Francisco
University of Washington
Eli Lilly and Company
Kaiser Permanente
NantCell, Inc.
City of Hope Medical Center
Tempus AI
Institut Bergonié
New Mexico Cancer Research Alliance
Pennington Biomedical Research Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trinity Health Michigan
NuCana plc
Elicio Therapeutics
Institut Bergonié
Eli Lilly and Company
Palleon Pharmaceuticals, Inc.
National Cancer Institute (NCI)
University of California, San Francisco
UNC Lineberger Comprehensive Cancer Center
Academic and Community Cancer Research United
Zhejiang University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hoffmann-La Roche
UNC Lineberger Comprehensive Cancer Center
Swiss Cancer Institute
University of Florida
NRG Oncology
Jilin University
University of Florida
NuCana plc
Hutchmed
Washington University School of Medicine
Intensity Therapeutics, Inc.
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Stanford University
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Hutchmed
Medical College of Wisconsin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NantBioScience, Inc.
NantCell, Inc.
VA Office of Research and Development